Malothu Narender

Dr. Malothu Narender

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2015 in Crystal Growth & Design
Verified
Journal Article
Closed access
JBJaswanth S. Bhandaru
Jaswanth S. Bhandaru
MNMalothu Narender
Malothu Narender
RARaghuram Rao Akkinepally
Raghuram Rao Akkinepally

1 February 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MNMalothu Narender
Malothu Narender
BSBhandaru Jaswanth S
Bhandaru Jaswanth S
umasankar kulandaiveluumasankar kulandaivelu
umasankar kulandaivelu
JMJojula Malathi
Jojula Malathi
ARAdidala Raghuram Reddy
Adidala Raghuram Reddy
RARaghuram Rao Akkinepally
Raghuram Rao Akkinepally

1 October 2018 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Closed access
MNMalothu Narender
Malothu Narender
umasankar kulandaiveluumasankar kulandaivelu
umasankar kulandaivelu
MJMalathi Jojula
Malathi Jojula
SGShravan Kumar Gunda
Shravan Kumar Gunda
RARaghuram Rao Akkinepally
Raghuram Rao Akkinepally
Two series of 3-substituted-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5] thieno[2,3-d]pyrimidin-4(3H)-one (6a-k) and 3-substituted-7,2-dimethyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one (7a-k) derivatives were synthesized and characterized using spectral data i.e., IR, 1H-, 13C-NMR, Mass and CHN elemental analyses. The synthesized compounds were evaluated for antibacterial activity against each of two strains of Gram-positive (Bacillus subtilis and Staphylococcus aureus) and Gram-negative (Escherichia coli and Klebsiella pneumoniae) bacteria and antimycobacterial activity screened against two strains i.e., Mycobacterium tuberculosis (MTB) H37Rv and an isoniazid-resistant clinical sample. Further to validate potentiality of our design was analyzed using molecular docking studies by taking crystal structure of MTB pantothenate synthetase (MTB-PS) (PDB: 3IVX). In this study, some compounds 6k (Minimum Inhibitory Concentration (MIC): MIC-22 µM), 7d (MTB: MIC-22 µM) and 7k (MTB: MIC-11 µM) showed potential antibacterial and antimycobacterial activities.

30 June 2023 in South African Journal of Botany
Verified
Journal Article
Open access
SGSarvan Kumar Guguloth
Sarvan Kumar Guguloth
MNMalothu Narender
Malothu Narender
NGNarayana Murthy Ganta
Narayana Murthy Ganta
KRKakarla Ramakrishna
Kakarla Ramakrishna
CGChakravarthi Guntupalli
Chakravarthi Guntupalli


1 January 2021 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
PDF file
SGSarvan Kumar Guguloth
Sarvan Kumar Guguloth
MNMalothu Narender
Malothu Narender
UKUmasankar Kulandaivelu
Umasankar Kulandaivelu
KRKoteswar Gsn Rao
Koteswar Gsn Rao
AAAnka Rao Areti
Anka Rao Areti
SNSadhana Noothi
Sadhana Noothi
In the present work, the preliminary phytochemical study and in vitro thrombolytic activity was conducted for Terminalia pallida Brandis leaves extract. In vitro thrombolytic was evaluated by clot lysis effect of different solvent extracts of Terminalia pallida Brandis leaves. In this study, streptokinase and distilled water were used as positive control and negative control, respectively. In vitro thrombolytic model of methanolic extract showed maximum clot lysis (95.43%±0.697) at test concentration (800μg/ml) in 72 hrs. Hydro alcoholic extract also showed potential clot lysis (90.43%±0.748) at similar test conditions. In addition, other plant extracts such as petroleum ether, ethyl acetate, chloroform extract showed moderate activity at 800 μg/ml concentration i.e., 65.56%±0.984, 70.16%±0.325 and 72.98%±0.985 clot lysis, respectively in 72 hrs. Streptokinase (SK) and water showed clot lysis maximum of 97.26%±0.974 and 41.33%±0.843 respectively. The present study reveals that the methanolic and hydro alcoholic extracts of Terminalia pallida Brandis leaves possesses potential thrombolytic activity.